Dr. Crystal L. Mackall

Dr. Crystal L. Mackall, MD, is an internationally renowned pediatric oncologist and immunologist, recognized as a global leader in cancer immunotherapy and T-cell biology. She serves as the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University, founding Director of the Stanford Center for Cancer Cell Therapy, and Director of the Parker Institute for Cancer Immunotherapy at Stanford. Dr. Mackall earned her medical degree from Northeast Ohio Medical University, completed her residency in Pediatrics at Akron Children's Hospital, and pursued fellowship training in Pediatric Hematology/Oncology at the National Cancer Institute (NCI), where she previously served as Chief of the Pediatric Oncology Branch. She is board-certified in Pediatrics and Pediatric Hematology/Oncology and is widely recognized for her pioneering work in advancing cellular immunotherapy for cancer.

A leading architect in the development of T-cell-based therapies, Dr. Mackall has driven transformative research that has shaped the evolution of CAR T-cell therapy, T-cell exhaustion, and immune regulation in pediatric and young adult malignancies. Her laboratory has made seminal contributions to understanding mechanisms of T-cell persistence, durability of immune responses, and resistance to cellular immunotherapies. Dr. Mackall has led clinical trials that have introduced innovative CAR T-cell constructs and combination strategies, extending the benefits of cell therapy to solid tumors and overcoming limitations of current immunotherapeutic approaches. She has authored over 300 peer-reviewed publications and is widely recognized for bridging fundamental immunology with clinical translation.

In addition to her scientific leadership, Dr. Mackall is a dedicated mentor and educator who has trained a generation of physician-scientists in cancer immunotherapy. Her collaborative leadership in national and international consortia continues to shape the direction of the field, driving forward innovative cellular immunotherapies that hold curative potential for patients with high-risk and refractory cancers.